Adient plc (ADNT): what the price requires

At today's price, Adient plc (ADNT) is priced for today's economics sustained for ~6.1 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ADNT

Headline

FieldValue
TickerADNT
CompanyAdient plc
Current price$19.13/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (mid-cycle)0.4%
Trailing margin (depressed year)-0.6%
Must persist for6.1y
Multiple paid57x mid-cycle operating income

Solve inputs: computed at a 7.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~10.8 years; the models below use their own rates.

How unusual the bet is: high

ReferenceValue
vs own history+3.63σ
sustained it ~6.1 years at this level25%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset3.13x4expensive
Earnings2.68x3expensive
Relative1.01x4expensive
Growth1.00x2justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.2%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
DCF Exit MultipleGrowth$29.440.65xyesExit EV/EBITDA: 28.3x / 30.3x / 32.3x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$15.401.24xyesP/E 20x (static sector reference · 2026-04), scenarios: 16.8x / 20.0x / 23.2x (bear / base = reference held flat / bull), EV/EBITDA 18.19x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$8.042.38xyesBV/sh $21.60, ROE (TTM) 3.4%, ke 9.3%
Two-Stage Excess ReturnAsset$4.943.87xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$14.081.36xyesRev $14.9B, growth 4% (input: historical growth; tapered), Terminal P/S: 0.1x / 0.1x / 0.1x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$7.922.42xyesEPS $0.66, growth 2% (input: historical EPS growth), PEG=15.86 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset$3.715.16xyesBV $21.60 + 5yr PV of (ROE (TTM) 3.4% − Kₑ 9.3%) × BV; BV grows 2.2%/yr
Graham NumberAsset$17.911.07xyes√(22.5 × EPS $0.66 × BVPS $21.60) — Graham's conservative floor
EV/EBITDA RelativeRelative$0.011913.00xyesEBITDA $0.14B × sector EV/EBITDA 13.0x (excluded from median)
FCF YieldEarnings$3.884.93xyesFCF $272.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$0.011913.00xyesSBC-adj FCF $0.23B (FCF $0.27B − SBC $0.04B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$21.300.90xyesEPS $0.66 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$282.560.07xyesRevenue $14.94B × sector P/S 1.5x
PEG Fair ValueRelative$24.750.77xyesEPS $0.66 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$7.142.68xyesEPS $0.66 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$2.4b
Net debt / NOPAT (after-tax)72.59x
Net debt / operating income (pre-tax)42.02x
Share count CAGR (buyback)-4.4%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 0.4%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

Capital allocation tells you what management believes, and Adient's actions say it sees the current earnings as a trough rather than the norm. Despite a near-breakeven year, the company has kept buying back stock, the share count has fallen about 4.4% a year, and it generates positive free cash flow even at the bottom of the cycle, with 2026 free-cash-flow guidance raised to about $130 million. Retiring shares while profits are depressed is a bet that the per-share economics look very different once auto production normalizes, and it concentrates the eventual recovery into fewer shares. That is the disciplined, contrarian version of capital allocation, and it is the spine of the bull case.

The franchise behind it is genuinely strong for a parts supplier. Adient is, in its own words, "a global leader in complete seat assembly and one of the largest in all major seating components including seating foam, metal structures, seat covers and seat mechanisms," and it supplies "all of the global OEMs" with longstanding relationships at BMW, Mercedes-Benz, Ford, and General Motors. A seat is a complex, safety-critical, just-in-time component that carmakers do not switch suppliers on lightly, so the incumbency is sticky. The company carries a mid-teens share of the global seating market and is pursuing share gains through onshored production, exactly the kind of program that adds revenue without a bet-the-company acquisition.

The recovery math is the payoff. Management is guiding to 2026 revenue of about $14.8 billion and adjusted EBITDA of about $885 million, and targeting an operating margin of 5.0% to 5.5% over the next two to three years from roughly breakeven today. On $15 billion of revenue, a few hundred basis points of margin is a large swing in absolute profit, and the company strives to claw it back through "improved operational performance, including commercial negotiations with Adient's customers and vendors." The bull case is a scaled, incumbent seating supplier at the bottom of its cycle, buying its own stock cheap, with a credible path to a margin recovery that would transform the earnings the equity is priced against.

Bear Case

The bear case is the structural reality of being a seat supplier: Adient sits downstream of the carmakers, and it absorbs their cycle without controlling it. Global vehicle production sets the volume, and the OEMs set the price, so when production softens or carmakers push for cost downs, the supplier eats the squeeze. The company says as much, that it must "offset the impact of lower production volumes and price reductions through improved operational performance," which is the polite description of running ever harder just to hold margin flat. A business whose customers dictate both volume and price has limited ability to defend its own profitability, and the trailing near-breakeven margin is what that looks like in a soft year.

The customer power cuts deeper than pricing. Adient warns that "large commercial settlements with Adient's customers likely would adversely affect" its results, and that customers can direct it to use specific components that are "difficult and/or expensive to re-source." That is a supplier with concentrated, powerful customers and constrained supply choices, a position with little leverage when negotiations turn adversarial. Layer on the macro headwinds management has already flagged, input-cost pressure tied to geopolitical conflict and a supply disruption, and the path to the targeted margin recovery is exposed to forces outside the company's control.

The leverage is what makes the cycle dangerous rather than merely unpleasant. Net debt of about $2.39 billion sits against trailing operating income that is actually negative, and interest coverage is barely above one, meaning the company's operating profit at the trough scarcely covers its interest bill. The valuation already prices a recovery: the price works out to roughly 59 times through-cycle operating income, far above what the company has actually delivered, and the asset and earnings-power methods both call it expensive while only the peer-multiple and growth lenses reach it. If the auto-production recovery is delayed or the margin target slips, a highly levered supplier with thin coverage has very little margin for error, and the equity, which sits behind $2.39 billion of debt, is where that error lands first.

Valuation

Adient has to be valued on normalized earnings, because the trailing ones are essentially zero, and the inversion does that by using through-cycle margins. On that basis the price of $20.78 (June 27, 2026) works out to about 59 times company-wide mid-cycle operating income, which implies operating profit growing near its self-funding ceiling for roughly seven years, a pace that runs well above what the company has actually delivered and that only about 22% of comparable fast-growers sustained. Even normalized, that is a demanding multiple, and it reflects how depressed the current earnings are: a near-breakeven trailing margin means almost any positive normalized number produces a high-looking multiple, so the figure is as much a statement about the trough as about the price.

The methods divide on whether to trust the recovery. The asset-value methods anchor on a book value of about $21.60 a share, just above the price, but the trough return on equity makes the assets look unproductive. The earnings-power method, capitalizing a normalized operating income near zero, calls the stock extremely expensive, which is the trough showing through. The peer-multiple and forward-growth methods, which credit a margin recovery, reach the price. So the static lenses say expensive and only the recovery-dependent methods justify the price, the familiar pattern for a deep cyclical at the bottom, where the entire valuation rests on the through-cycle earnings being far above the trailing ones.

Solvency is the part the bull case cannot wave away. Net debt of about $2.39 billion sits against trailing operating income that is negative, and interest coverage is only about 1.1 times, so at the trough the company's operating profit barely services its debt. It is generating positive free cash flow and buying back stock, which argues the cash generation is better than the GAAP operating line suggests, but the leverage means the equity is a thin claim behind a large fixed obligation. The downside is not bounded by a comfortable balance sheet; it is bounded only by the recovery arriving. The decisive question is timing: whether auto production and the targeted 5.0% to 5.5% margin show up before the leverage becomes the story, because a highly levered cyclical priced for normalization has no cushion if normalization is late.

Catalysts

The constructive catalyst is a guidance raise that points toward the recovery. Adient lifted its 2026 outlook, with revenue guidance increased to about $14.8 billion, adjusted EBITDA to about $885 million, and free cash flow to about $130 million. Management also laid out a margin target of 5.0% to 5.5% over the next two to three years and pointed to share gains through onshored production, with some targeted programs potentially doubling revenue contributions from those areas. Those are the levers that would turn the trough earnings into the normalized earnings the valuation assumes.

The offsetting catalysts are cost headwinds management has already quantified: about $35 million of input-cost pressure, roughly $25 million tied to Middle East conflict and $10 million from a LyondellBasell supply disruption. For a business with thin margins, even modest input-cost surprises matter, and they push against the margin-expansion path. The variable to watch is global vehicle production, because Adient's volume, and therefore the operating leverage in either direction, is set by how many cars its customers build.

Sentiment is moderately positive with wide dispersion. The covering analysts lean Buy to Moderate Buy, with a median target meaningfully above the current price and a notably wide range, from the low $20s to the high $60s, reflecting deep disagreement about the pace of the recovery. Citigroup raising its target to $33 in April 2026 captures the bull view that the margin recovery is real; the wide spread of targets captures the genuine uncertainty over when, and whether, the through-cycle earnings actually arrive.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

company FY2026 guidance, 2026 · company commentary, 2026 · analyst consensus, 2026

View the full interactive ADNT report on boothcheck